What question did this study set out to answer?

This study aims to compare the effects of a new high-concentration insulin aspart formulation with standard insulin in type 2 diabetes.

August 1, 2026Diabetes Obesity and MetabolismOpen Access

A New Highly Concentrated Insulin Aspart AT278 (500 U/ mL ) Demonstrates Ultra‐Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI

View Full Paper

Ask AI

Bookmark

This study aims to compare the effects of a new high-concentration insulin aspart formulation with standard insulin in type 2 diabetes.
Single-centre, randomised, double-blind crossover design
41 overweight and obese individuals with type 2 diabetes enrolled
12-hour euglycaemic clamp to measure pharmacokinetics and pharmacodynamics
AT278-U500 showed faster insulin absorption at 9 minutes compared to InsAsp-U100 at 35 minutes and HumIns-U500 at 55 minutes.
Glucose-lowering effect in the first hour for AT278-U500 was significantly higher: AUC GIR,0-60min treatment ratio 2.02 against InsAsp-U100 and 3.91 against HumIns-U500.
No significant relationship between BMI and AUC GIR,0-60min for AT278-U500, unlike InsAsp-U100 where the relationship was significant (slope −0.142, p < 0.0001).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial evaluates ultra-rapid insulin aspart's effects on glucose control in type 2 diabetes, indicating promising efficiency regardless of BMI.

Cite This Study

Švehlíková et al. (2026) studied this question.

synapsesocial.com/papers/6a6d9874e258b358b3c6bd1e https://doi.org/10.1111/dom.71150

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates ultra-rapid insulin aspart's effects on glucose control in type 2 diabetes, indicating promising efficiency regardless of BMI.

A New Highly Concentrated Insulin Aspart AT278 (500 U/ mL ) Demonstrates Ultra‐Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI

Key Points

Discussion

Implication

Cite This Study

A New Highly Concentrated Insulin Aspart AT278 (500 U/ mL ) Demonstrates Ultra‐Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider